Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Aug 18;29(Suppl 2):21–27. doi: 10.1002/clc.4960291405

Strategies for primary and secondary stroke prevention

Lawrence M Brass 1,†,✉
PMCID: PMC6654346  PMID: 17436823

Abstract

Of the 55 million deaths that occur annually, 1 in 10 is attributable to stroke. As a consequence, cerebrovascular disease is the second leading cause of death worldwide, and stroke is among the most devastating consequences of vascular disease, causing long‐term disability and incurring high personal, societal, and financial costs. However, stroke is a highly preventable disease in the majority of patients. The goal of stroke prevention strategies is to identify high‐risk patients through the presence of modifiable and nonmodifiable risk factors and to target these modifiable risk factors through the use of appropriate pharmacologic and nonpharmacologic interventions. Clinical and epidemiologic studies point toward three major risk‐reducing pharmacologic therapies that together may dramatically reduce stroke risk. First, landmark clinical trials have demonstrated that the reduction of blood pressure in persons at risk for cerebrovascular disease significantly reduces stroke risk. Second, ample evidence supports the use of antiplatelet therapy, such as aspirin, in patients at high risk for a cerebrovascular event. Third, an abundance of data suggests that lipid‐lowering therapy with a statin reduces stroke risk in most moderate‐ to high‐risk patients regardless of baseline cholesterol levels. Together, these data suggest that intensive therapy with agents from multiple drug classes that target two or more risk factors for cerebrovascular disease may provide additive—or even synergistic—reductions in stroke risk.

Keywords: stroke, primary prevention, secondary prevention, pharmacologic therapy

Full Text

The Full Text of this article is available as a PDF (813.4 KB).

References

  • 1. American Heart Association : Heart Disease and Stroke‐Statistical Update 2004. Dallas, Texas: American Heart Association, 1–52, 2004 [Google Scholar]
  • 2. World Health Organization : The WHO stroke surveillance system. World Health Organization; 2004;August 23 [Google Scholar]
  • 3. Bonita R: Epidemiology of stroke. Lancet 1992; 339 (8789): 342–344 [DOI] [PubMed] [Google Scholar]
  • 4. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM: Dementia after ischemic stroke: A population‐based study in Rochester, Minnesota(1960–1984). Neurology 1996; 46 (1): 154–159 [DOI] [PubMed] [Google Scholar]
  • 5. Tatemichi TK, Park M, Bagiella E, Desmond DW, Stern Y, Sano M, Hauser WA, Mayeux R: Risk of dementia after stroke in a hospitalized cohort: Results of a longitudinal study. Neurology 1994; 44 (10): 1885–1891 [DOI] [PubMed] [Google Scholar]
  • 6. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: A risk profile from the Framingham Study. Stroke 1991; 22 (3): 312–318 [DOI] [PubMed] [Google Scholar]
  • 7. Sacco RL: Ischemic stroke In Handbook of Neuroepidemiology (Eds. Gorelick PB, Alter MA.), pp. 77–119. New York, N.Y.: Marcel Dekker, 1994. [Google Scholar]
  • 8. Wolf PA: Epidemiology of stroke In Stroke: Pathophysiology, Diagnosis, and Management, 2nd ed. (Ed. Bamett HJM.), pp. 3–27. Philadelphia: Churchill Livingstone, 1992. [Google Scholar]
  • 9. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH: Familial aggregation of stroke. The Framingham Study. Stroke 1993; 24 (9): 1366–1371 [DOI] [PubMed] [Google Scholar]
  • 10. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A: Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet 1997; 350 (9080): 757–764 [DOI] [PubMed] [Google Scholar]
  • 11. PROGRESS Collaborative Group : Randomised trial of a perindo‐pril‐based blood pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 (9287): 1033–1041 [DOI] [PubMed] [Google Scholar]
  • 12. PROGRESS Collaborative Group : Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163 (9): 1069–1075 [DOI] [PubMed] [Google Scholar]
  • 13. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J: Use of ramipril in preventing stroke: Double blind randomised trial. Br Med J 2002; 324 (7339): 699–702 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe‐Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359 (9311): 995–1003 [DOI] [PubMed] [Google Scholar]
  • 15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium‐channel blocker vs. diuretic: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002; 288 (23): 2981–2997 [DOI] [PubMed] [Google Scholar]
  • 16. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Blood Pressure Lowering Arm (ASCOT‐BPLA): A multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895–906 [DOI] [PubMed] [Google Scholar]
  • 17. Antithrombotic Trialists' Collaboration : Collaborative meta‐analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324 (7329): 71–86 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143 (1–2): 1–13 [DOI] [PubMed] [Google Scholar]
  • 19. CAPRIE Steering Committee : A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348 (9038): 1329–1339 [DOI] [PubMed] [Google Scholar]
  • 20. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias‐Guiu J, Rupprecht H: Management of Atherothrombosis with Clopidogrel in High‐Risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke (MATCH): Study design and baseline data. Cerebrovasc Dis 2004; 17 (2–3): 253–261 [DOI] [PubMed] [Google Scholar]
  • 21. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ: Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest 2004; 126 (3 suppl): 429S–456S [DOI] [PubMed] [Google Scholar]
  • 22. Halperin JL: Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003; 146 (3): 431–438 [DOI] [PubMed] [Google Scholar]
  • 23. Olsson SB: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non‐valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 2003; 362 (9397): 1691–1698 [DOI] [PubMed] [Google Scholar]
  • 24. Wannamethee SG, Shaper AG, Ebrahim S: HDL‐cholesterol, total cholesterol, and the risk of stroke in middle‐aged British men. Stroke 2000; 31 (8): 1882–1888 [DOI] [PubMed] [Google Scholar]
  • 25. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovem PG, Sharrett AR: Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003; 34 (3): 623–631 [DOI] [PubMed] [Google Scholar]
  • 26. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD: Serum cholesterol levels and six‐year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320 (14): 904–910 [DOI] [PubMed] [Google Scholar]
  • 27. Benfante R, Hwang LJ, Masaki K, Curb JD: To what extent do cardiovascular risk factor values measured in elderly men represent their midlife values measured 25 years earlier? A preliminary report and commentary from the Honolulu Heart Program. Am J Epidemiol 1994; 140 (3): 206–216 [DOI] [PubMed] [Google Scholar]
  • 28. Horenstein RB, Smith DE, Mosca L: Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke 2002; 33 (7): 1863–1868 [DOI] [PubMed] [Google Scholar]
  • 29. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J: Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation 2001; 103 (3): 387–392 [DOI] [PubMed] [Google Scholar]
  • 30. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333 (20): 1301–1307 [DOI] [PubMed] [Google Scholar]
  • 31. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Wamica JW, Arnold JMO, Wun C, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335 (14): 1001–1009 [DOI] [PubMed] [Google Scholar]
  • 32. LIPID Study Group : Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long‐Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998; 339 (19): 1349–1357 [DOI] [PubMed] [Google Scholar]
  • 33. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, Mclnnes GT, Mehlsen J, Nieminen M, O'Brien E, Österfren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower‐than‐average cholesterol concentrations, in the Anglo‐Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT‐LLA): A multicentre randomised controlled trial. Lancet 2003; 361 (9364): 1149–1158 [DOI] [PubMed] [Google Scholar]
  • 34. Heart Protection Study Collaborative Group : MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: A randomised placebo‐controlled trial. Lancet 2002; 360 (9326): 7–22 [DOI] [PubMed] [Google Scholar]
  • 35. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH: Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001; 87 (7): 819–822 [DOI] [PubMed] [Google Scholar]
  • 36. Ovbiagele B, Saver JL, Fredieu A, Suzuki S, McNair N, Dandekar A, Razinia T, Kidwell CS: PROTECT: A coordinated stroke treatment program to prevent recurrent thromboembolic events. Neumlogy 2004; 63 (7): 1217–1222 [DOI] [PubMed] [Google Scholar]
  • 37. Ovbiagele B, Saver JL, Fredieu A, Suzuki S, Selco S, Rajajee V, McNair N, Razinia T, Kidwell CS: In‐hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow‐up. Stroke 2004; 35 (12): 2879–2883 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES